<DOC>
	<DOC>NCT02970643</DOC>
	<brief_summary>The purpose of this study is to determine whether Palonosetron and Olanzapine without dexamethasone for the Prevention of moderate risk Chemotherapy-Induced Nausea and vomiting.</brief_summary>
	<brief_title>Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN</brief_title>
	<detailed_description>This study was designed to evaluate efficacy and safety of olanzapine compared with 5-hydroxytryptamine3 receptor antagonist for prevention of moderate risk chemotherapy induced nausea and vomiting.</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>European Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 no severe cognitive compromise Moderate risk chemotherapy induced chemotherapy induced nausea and vomiting in 1st cycle Confirmed histology European Cooperative Oncology Group (ECOG) performance status of 3 and 4 Nausea or vomiting in the 24 hours before enrollment History of Nausea or vomiting Grade 3 before previous chemotherapy Known history of central nervous system disease (e.g., brain metastases or a seizure disorder) Bowel obstruction Serum creatinine level of 2.0 mg per deciliter (177 Î¼mol per liter) or more Aspartate or alanine aminotransferase level that was more than 3 times the upper limit of the normal range Treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, a phenothiazine, or a butyrophenone within 30 days before enrollment Treatment with another antiemetic agent before 48 hours before enrollment Uncontrolled severe infection or uncontrolled severe comorbidity Concurrent abdominal radiotherapy Known hypersensitivity to olanzapine, palonosetron Known cardiac arrhythmia, uncontrolled congestive heart failure, or acute myocardial infarction within the previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Olanzapine</keyword>
	<keyword>Chemotherapy-Induced Nausea and Vomiting</keyword>
	<keyword>Moderate risk</keyword>
</DOC>